Patents by Inventor Kimberly A. Walker
Kimberly A. Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11406221Abstract: A utility skirt for a wire chafing dish rack, wherein the utility skirt is folded around the wire chafing dish rack. The utility skirt having an upper edge, a lower edge, a left edge, and a right edge defining an area of the utility skirt. The upper edge of the utility skirt runs along the upper rim of the wire chafing dish rack. Three tabs extend from the left edge and three slits are made in the utility skirt near the right edge. The three tabs can interlock with the three slits for coupling the left edge to the right edge. Three fold lines divide the utility skirt into four sections, each of the four sections corresponds to the four sides of the wire chafing dish rack. Rim-tabs from the upper edge of the utility skirt folds over the upper rim for supporting the utility skirt over the wire chafing dish rack.Type: GrantFiled: January 23, 2021Date of Patent: August 9, 2022Inventor: Kimberly Walker Craig
-
Publication number: 20210137308Abstract: A utility skirt for a wire chafing dish rack, wherein the utility skirt is folded around the wire chafing dish rack. The utility skirt having an upper edge, a lower edge, a left edge, and a right edge defining an area of the utility skirt. The upper edge of the utility skirt runs along the upper rim of the wire chafing dish rack. Three tabs extend from the left edge and three slits are made in the utility skirt near the right edge. The three tabs can interlock with the three slits for coupling the left edge to the right edge. Three fold lines divide the utility skirt into four sections, each of the four sections corresponds to the four sides of the wire chafing dish rack. Rim-tabs from the upper edge of the utility skirt folds over the upper rim for supporting the utility skirt over the wire chafing dish rack.Type: ApplicationFiled: January 23, 2021Publication date: May 13, 2021Inventor: KIMBERLY WALKER CRAIG
-
Publication number: 20130139325Abstract: A combination mallet and ax device wherein the mallet has an opening adapted to selectively receive the ax.Type: ApplicationFiled: December 6, 2011Publication date: June 6, 2013Inventors: Todd Walker, Kimberly Walker
-
Publication number: 20110006004Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: July 12, 2010Publication date: January 13, 2011Applicant: HEMAVATION, LLCInventors: Alan A. Davidner, Kimberly A. Walker, Scott R. Mallett
-
Patent number: 7753869Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: GrantFiled: April 24, 2007Date of Patent: July 13, 2010Assignee: Hemavation, LLCInventors: Alan A. Davidner, Kimberly A. Walker, Scott R. Mallett
-
Publication number: 20070190050Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: April 24, 2007Publication date: August 16, 2007Applicant: HEMA VATION, LLCInventors: Alan Davidner, Kimberly Walker, Scott Mallett
-
Patent number: 7229427Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: GrantFiled: March 17, 2003Date of Patent: June 12, 2007Assignee: HemavationInventors: Scott R. Mallett, Alan A. Davidner, Kimberly A. Walker
-
Patent number: 7207964Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: GrantFiled: March 17, 2003Date of Patent: April 24, 2007Assignee: Hemavation, LLCInventors: Alan A. Davidner, Kimberly A. Walker, Scott R. Mallett
-
Patent number: 7201730Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50–75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: GrantFiled: March 17, 2003Date of Patent: April 10, 2007Assignee: Hemavation, LLCInventors: Alan A. Davidner, Kimberly A. Walker, Scott R. Mallett
-
Publication number: 20060210424Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: May 3, 2006Publication date: September 21, 2006Inventors: Scott Mallett, Alan Davidner, Kimberly Walker
-
Publication number: 20050277863Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: December 15, 2005Inventors: Alan Davidner, Kimberly Walker, Scott Mallett
-
Publication number: 20040186412Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Inventors: Scott R. Mallett, Alan A. Davidner, Kimberly A. Walker
-
Publication number: 20040186410Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Inventors: Alan A. Davidner, Kimberly A. Walker, Scott R. Mallett
-
Publication number: 20040182784Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Inventors: Kimberly A. Walker, Alan A. Davidner, Scott R. Mallett
-
Publication number: 20040182783Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodbome microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Inventors: Kimberly A. Walker, Alan A. Davidner, Scott R. Mallett
-
Publication number: 20040185426Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Inventors: Scott R. Mallett, Alan A. Davidner, Kimberly A. Walker
-
Publication number: 20040186411Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Inventors: Scott R. Mallett, Alan A. Davidner, Kimberly A. Walker
-
Publication number: 20040185041Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Applicant: Henna Vation, LLCInventors: Kimberly A. Walker, Alan A. Davidner, Scott R. Mallett
-
Publication number: 20040186407Abstract: A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.Type: ApplicationFiled: March 17, 2003Publication date: September 23, 2004Inventors: Kimberly Walker, Alan A. Davidner, Scott R. Mallett